The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Mounjaro is approved as an adjunct to a reduced-calorie diet and increased physical activity for adults with an initial body ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

US pharmaceutical giant Eli Lilly has launched its blockbuster diabetes and weight-loss drug, Mounjaro, in India following ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

This study provides valuable guidance for doctors and patients when choosing diabetes medications. It confirms that ...

(a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee (R) (insulin glargine-yfgn injection) as the first interchangeable biosimilar ...

Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper versions of biologics such as Humira and Stelara.

随着经济社会发展，物质生活极大丰富，生活方式也在不断改变，2型糖尿病（T2DM）的发病率越来越高，且合并肥胖、高血压、心血管疾病等慢性疾病患者比例增加，需要临床对患者进行综合管理。T2DM病理生理机制复杂，降糖药物通过作用于不同的靶点发挥作用[1]。